EGFR and non-small cell lung carcinoma: Our findings were consistent with previous clinical trials and real-world analysis, and we also confirmed the clinical efficacy of osimertinib in acquired T790M-mutant NSCLC patients who had progressive disease to first-line EGFR-TKI.